Comparing Zenas BioPharma (NASDAQ:ZBIO) & VistaGen Therapeutics (NASDAQ:VTGN)

Zenas BioPharma (NASDAQ:ZBIO) and VistaGen Therapeutics (NASDAQ:VTGN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Valuation and Earnings

This table compares Zenas BioPharma and VistaGen Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10.00 million	193.13	-$377.74 million	($8.99)	-3.30
VistaGen Therapeutics	$1.27 million	12.87	-$69.68 million	($1.66)	-0.22

VistaGen Therapeutics has lower revenue, but higher earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Zenas BioPharma has a beta of -1.04, meaning that its stock price is 204% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Zenas BioPharma and VistaGen Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1	2	6	0	2.56
VistaGen Therapeutics	1	4	0	0	1.80

Zenas BioPharma presently has a consensus target price of $45.71, indicating a potential upside of 54.28%. VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 157.87%. Given VistaGen Therapeutics’ higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Zenas BioPharma.

Profitability

This table compares Zenas BioPharma and VistaGen Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%

Insider & Institutional Ownership

78.4% of VistaGen Therapeutics shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Zenas BioPharma beats VistaGen Therapeutics on 8 of the 14 factors compared between the two stocks.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.